{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-24-000082","form_type":"8-K","ticker":null,"cik":"0000910267","company_name":"TITAN PHARMACEUTICALS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.249015+00:00","generated_at":"2026-06-07T02:48:41.307122+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Titan Pharmaceuticals effects 1-for-20 reverse stock split; CUSIP changes to 888314705","bullets":["Reverse split at 1-for-20 ratio effective January 8, 2024 at 5:00 p.m. ET.","Stock continues trading on Nasdaq under symbol TTNP with new CUSIP 888314705.","Approved by stockholders at special meeting on December 27, 2023 and by the Board on November 16, 2023.","Continental Stock Transfer & Trust is exchange agent for the reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-24-000082","json":"https://secwatch.observer/filing/0001829126-24-000082.json","markdown":"https://secwatch.observer/filing/0001829126-24-000082.md","text":"https://secwatch.observer/filing/0001829126-24-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/0001829126-24-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/titanpharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:48:41.307122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b952e4126baae1df01b723c71bbd82f42e6e1c1c","claim":"TITAN PHARMACEUTICALS INC: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock, effective January 8, 2024 at 5:00 p.m. Eastern Time (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Titan Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-20 (the “Reverse Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/910267/000182912624000082/0001829126-24-000082-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}